DocGo Inc. (DCGO) Earnings Call Transcript & Summary
November 7, 2024
Earnings Call Speaker Segments
Mike Cole
executiveThank you, Operator. Before I hand things over to management, I'd like to offer a few comments about forward-looking statements. Everything shared on this conference call that isn't a statement of historical fact counts as a forward-looking statement. Terms such as may, will, plan, potential, could, goal, outlook, design, anticipate, aim, believe, estimate, expect, intend, guidance, confidence, target, project, and similar expressions might be used to flag these forward-looking statements. Such forward-looking statements don't guarantee future performance, and we can't assure you that our plans, intentions, outcomes, results, or expectations will be achieved or realized. Forward-looking statements carry inherent exposure to significant risks, uncertainties, and assumptions, a great many of which lie outside our control and could cause our actual results or outcomes, or when results or outcomes occur, to differ materially from what our forward-looking statements contain. Among these risks, uncertainties, and assumptions are, without limitation, those addressed in our risk factors and elsewhere in DocGo's annual report on Form 10-K, quarterly reports on Form 10-Q, and other reports and statements DocGo has filed with the SEC, to which we direct your attention. Actual outcomes and results, or when results or outcomes occur, may differ materially from what these forward-looking statements express or imply; furthermore, today's call includes references to non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures appear directly as part of this call or are included in our earnings release or the current report on Form 8-K that contains our earnings release, which is posted on our website, docgo.com, and also filed with the SEC. The information in this call is accurate only as of the date discussed. Investors shouldn't assume statements will stay relevant and operative later on. We assume no obligation to update any information discussed in this call to reflect events or circumstances occurring after the date of this call, or to reflect new information or the occurrence of unanticipated events, except to the extent the law requires. At this point, it's my pleasure to turn the call over to Mr. Lee Bienstock, CEO of DocGo. Lee, please go ahead.
Lee Bienstock
executiveThank you, Mike, and I'm glad everyone could join us today. Our third-quarter results were strong across all customer verticals, with revenue reaching $138.7 million and adjusted EBITDA coming in at $17.9 million. One highlight worth calling out is the remarkable progress we've made on care gap closure programs with a range of payers. The early signals from these efforts continue to look very promising — assigned lives again grew by more than twofold from Q2 to Q3, and we've now crossed the 500,000 patient mark. Since our last earnings report, the average number of completed care gap visits per week has doubled as of today. We expect to exit the year at a pace of 1,000 visits each week. Over just the past 2 months, we've established new hubs along the West Coast, from San Diego through Los Angeles up to Sacramento, to meet this demand, and we're getting ready for additional expansion into the Northeast. Today, we refined our 2024 guidance to between $620 million and $630 million in revenue, with adjusted EBITDA of $70 million to $75 million, while raising our cash flow from operations expectation to $90 million to $100 million, up from $80 million to $90 million. Several of the programs we operate that relate to migrants are taking more time to wrap up than we first expected. Because of that, our projection for migrant-related revenue in 2024 now stands at $360 million to $390 million, which is higher than the $320 million to $350 million we had forecast previously. Offsetting this is a decrease we expect of a similar size within our municipal population health programs that serve non-migrants. As a result, our base business forecast for 2024 — made up of transportation and non-migrant mobile health — drops to $240 million to $260 million, compared with the $280 million to $300 million we had projected before. I want to be clear about one thing: none of this changes what we expect for total consolidated revenue in 2024 — it only shifts how that revenue breaks down between migrant and non-migrant sources. As a concrete illustration, our contract with HPD, which was reduced by roughly 50% in May, had been expected to mostly wrap up in late Q3; we now anticipate it concluding in late December. As migrant-related programs taper off, we intend to redeploy those resources toward new non-migrant-related programs; this is purely a timing issue. Turning to 2025, we released consolidated revenue guidance today of $410 million to $450 million, factoring in an expected migrant-related revenue contribution of $50 million. I'd like to stress that our migrant-related work in 2025 centers on health care and is fully consistent with our population health vertical service offerings, such as infectious disease screening, behavioral health assessments, vaccinations and urgent care. Taking everything into account, we're either hitting or beating the combined financial goals we set across each of our 3 customer verticals, and we feel tremendous excitement about the way we ran things operationally during this quarter as well as the strength of our pipeline. The momentum behind cash generation remains very powerful — roughly $31 million came in from operations over this period. Our cash and cash equivalents are now past $108 million, up from $86 million the quarter before and $59 million in Q1 of this year. Back in 2023 and continuing into early 2024, we directed substantial funds toward working capital for the programs tied to migrants. That trend has reversed at this point, producing really strong cash flow, and it should continue in that direction through the start of 2025. Because our balance sheet is in good shape, we have the capacity to support our expansion initiatives, pursue possibilities within a robust pipeline, repurchase additional stock, fund fresh strategic alliances and reduce what we owe on our credit facility. As is my usual habit, I want to spend a short while walking through the 3 primary customer verticals we serve: payers and providers, municipal population health and hospital systems. Regarding the payer and provider segment, like I mentioned previously, we are accelerating infrastructure expansion because these offerings have been received with such enthusiasm. In recent developments, only a month ago, a major national insurer revealed a considerable decline in its Medicare Advantage star ratings, and per analysts, that might cut its 2026 EBITDA by up to 50%. Every insurer nationwide is focused on this vital issue, and we think our care gap closure programs are a perfect answer for assisting with plan rating improvements and possibly delivering a substantial favorable financial effect for our clients. Demand isn't in question—what we're zeroed in on now is scaling up capacity to serve it. As we've said before, we expect to finish 2024 running at 1,000 visits each week, and with our care gap closure program, we'll be positioned to hit or beat our 65,000-visit target for 2025. On top of that, Q3 marked the start of PCP patient enrollment, and we've got deals in progress with payer partners that put us on track to reach 10,000 PCP patients in 2025. We also still expect to achieve our objective of 70,000 patients monitored across our virtual care management programs by the close of 2025. When it comes to the partnerships we've built with mobile health plans, there's a cycle that keeps benefiting everyone involved. Patients get the advantage of receiving excellent care conveniently at home. Insurers come out ahead because their members get healthier, and they also have a chance to boost HEDIS scores along with star ratings. Meanwhile, DocGo keeps advancing its goal of delivering top-quality care to everyone. What's more, these initiatives set DocGo up to grow into value-based care agreements with the insurance companies we work with down the road — something that matters a great deal for our long-term expansion and vision. As an illustration of how these plans are becoming reality, we've been running a transitional care management program aimed at lowering readmissions at one hospital in Southern California for L.A. We work with L.A. Care, a health plan covering 2.5 million members. Because we achieved a reduction of over 50% in emergency department visits for patients at this hospital, we have entered into an expanded contract with L.A. Care. This contract means our transitional care management offering will be available at additional hospitals, providing care gap closure services for members of L.A. Care, and we will also launch a mobile health initiative designed to improve management of certain of their member groups that are highest-risk and most complex. Now, regarding our municipal population health vertical, Q3 delivered a number of positive indicators. Coming up in the fall, we plan to expand the mobile X-ray initiative across New York City, and we've secured a fourth-year renewal of the Street Health Outreach + Wellness contract, which allows us to continue operating that award-winning mobile health care program serving unhoused and underserved populations throughout NYC. Additionally, just this week, the New Mexico Department of Health granted us an expansion that broadened the scope of our existing contract for clinical services at their public health offices. All together, we continue to leverage our clinical expertise and Mobile Health care approach so that care extends to people outside traditional health care settings. In the third quarter alone, our care was provided across over 215,000 visits spanning medical and behavioral health, including services such as x-rays, vaccinations, urgent care, and depression screenings, plus others.
Lee Bienstock
executiveIn this customer segment, we've also achieved quite a bit with Project Prime, an effort aimed at finding big government contractors who already have projects underway and might gain from subcontracting the municipal population health pieces of that work to DocGo. This strikes us as a very sizable opportunity, and we anticipate starting to bring in revenue from this effort in early 2025. Over in our hospital segment, there are quite a few small- to medium-sized contracts either already signed or very near signing, which gives us solid visibility toward hitting our 2025 growth estimates. Beyond new contracts, we've also recently grown in the Northeast with a major customer and are continuing our build-out in the Dallas market. The feedback we got from customers on our newly launched contracts in Dover, Delaware was exceptional, which is great to see and encouraging as we expand our presence in that market. We've also made meaningful upgrades to our technology, so customers can now track a network of providers inside our proprietary technology platform, in addition to being able to dispatch both medical transportation and mobile health resources — a combination we think is unique in our industry. For a long time, we've believed our proprietary technology could work as a stand-alone SaaS product capable of generating revenues for us in markets where we lack a physical presence, and we expect that to start in the fourth quarter. Before handing things to Norm, I'd also like to spend a moment on the addition of Dr. Stephen Klasko as our new Chair of the Board. Previously CEO of Jefferson Health and a special adviser at venture capital firm General Catalyst, Dr. Klasko carries extensive health care experience and a vast network that can assist DocGo in many ways. He's also a vocal advocate for health care at any address and a pioneering AI technologist who could potentially optimize patient care and boost operational efficiency; and we look forward to gaining from his guidance and vast industry knowledge. We couldn't be more excited to have Dr. Klasko on board, and we're off to a great, great start. I'll now hand things to Norm to cover the financial results. Norm, please go ahead.
Norman Rosenberg
executiveThanks, Lee, and good afternoon everyone. For the third quarter of 2024, total revenue came in at $138.7 million. That's a 26% decline versus the third quarter of 2023, though it matched what we had expected, and the reason was the wind down we anticipated in migrant-related projects. Mobile Health revenue in the third quarter of 2024 reached $90.7 million, a drop of 35% from the third quarter of 2023, again caused by the planned wind-down of migrant-related work. As we've mentioned on earlier earnings calls, those migrant-related revenues started falling sequentially in Q2, which reflected the wind down of certain sites in New York City that got underway in mid-May. We expect these migrant-related revenues to keep declining sequentially through the remainder of 2024 and on into 2025. Looking at the year-to-date period through September, Mobile Health revenues are up 20% in 2024. Transportation services revenue rose to $48 million in Q3 of 2024, roughly 2% above the transport revenues we posted in the third quarter of 2023. Our biggest gains came both in large markets, including the U.K., and in certain smaller markets such as Tennessee and Delaware. Over the first 9 months of 2024, transportation revenues climbed 9% compared with the prior year period. In the past, we've experienced stretches of growth exceeding our 15% annual target, and more lately we've been digesting that strong growth. We have a number of recent contract wins that make us confident we can sustain our 15% annual revenue growth expectation as we head into 2025. Net income was $4.5 million in Q3 of 2024, versus net income of $4.6 million in the third quarter of 2023, since we managed to successfully offset the revenue decline's impact through significantly better gross margins. Adjusted EBITDA for the third quarter of 2024 was $17.9 million, an increase from $16.7 million in last year's third quarter. Adjusted EBITDA margin reached 12.9% in Q3, higher than 8.9% in the third quarter of 2023. That marked the fourth consecutive quarter of double-digit adjusted EBITDA margins. Total GAAP gross margin percentage in the third quarter of 2024 was 33%, a strong rise from 27.2% in the third quarter of 2023. Adjusted gross margin was 36%, versus 29.5% in the third quarter of 2023. Because many of our mobile health projects have matured over the course of 2024, we've realized solid improvements in subcontractor costs. In the third quarter of 2024, subcontracted labor represented 33% of total labor costs, compared with 41% in the third quarter of 2023. Subcontracted labor has fallen sequentially since it peaked in the fourth quarter of last year at roughly 44% of total labor costs. In the third quarter of 2024, adjusted gross margin for the Mobile Health segment was 38.8%, compared with 28.8% in the third quarter of 2023. For Mobile Health, adjusted gross margins have risen across 4 straight quarters now. Over in Transportation, adjusted gross margins stood at 30.7% in Q3 2024, which is lower than the 31.7% recorded in Q3 of 2023, yet transportation margins did climb 160 basis points relative to where they sat in Q2 2024. Even so, leftover subcontractor costs in one of our markets continued to weigh on them. That said, by the time the third quarter wrapped up, those subcontractor costs were almost gone, since we managed to close staffing gaps through newly hired field personnel. Turning to operating costs, SG&A represented 28.7% of total revenues during the third quarter of 2024, which is above the 24.8% figure from the third quarter of 2023. In absolute dollar terms, though, operating expenses dropped 14% year-over-year, helped in part by targeted reductions in force carried out during the first half of 2024, bringing operating expenses down to their lowest quarterly levels since the first quarter of 2023. We keep actively managing our operating expenses as the migrant programs wind down. That said, with revenues expected to come in sequentially lower, SG&A may well rise as a percentage of revenues across the next few quarters, and that is factored into our adjusted EBITDA margin expectation of 8% to 10% in 2025. Our balance sheet stands out as the biggest financial highlight of the third quarter, where we made another significant step forward. As of September 30, 2024, total cash and cash equivalents, including restricted cash, came to $108.6 million, versus $85.8 million at the close of the second quarter of 2024. By the end of Q3, our total cash balance exceeded where it was a year earlier by more than $40 million. Solid collections during the third quarter drove this cash increase, and they also brought about a decline in our accounts receivable compared with both the end of the second quarter and the levels seen at the end of 2023. At quarter end, accounts receivable from the various migrant programs totaled approximately $170 million, compared to $185 million in accounts receivable from the various migrant programs at the end of Q2. With these migrant-related programs continuing to wind down over the remainder of 2024, our balance sheet should keep benefiting as we collect this AR and move our days sales outstanding, or DSO, closer in line with historical levels. As we collect older, larger invoices and as our cash outflows decrease alongside lower migrant project expenditures, we expect our cash balance to keep increasing. We now expect to generate cash flow from operations of $90 million to $100 million in 2024. Since we've generated $57 million in cash flow from operations through the first 9 months of the year, we're looking at an additional $33 million to $43 million in cash flow from operations in the fourth quarter. To make a comparison, our operations produced $37 million in cash flow during the second quarter, plus an additional $31 million in the third quarter. With the higher cash balances we now hold, we'll be able to put money into a few of the opportunities we're assessing right now to expand our business. With that, I want to hand the call back to Lee for a moment.
Lee Bienstock
executiveThank you, Norm. Before handing things back to the operator for the Q&A portion, I'd like to wrap up by noting that Q3 represents 1 year since I became DocGo's CEO. During those 12 months, this company has achieved remarkable things — among them moving more than 1.1 million patients and supporting care delivery across over 820,000 mobile health encounters. Reaching that volume of individuals is a tangible demonstration of what we set out to do: deliver top-tier, easily reachable care to everyone. DocGo's vertically integrated mobile health care offering, driven by a best-in-class proprietary technology platform alongside compassionate clinical providers, has an incredible product market fit; we hold strong ties with an enviable roster of customers and post a patient Net Promoter Score of 85, which says a great deal about how well we deliver service, and we maintain a positive, employee-centric company culture, as shown by our workplace excellence awards. I'm confident we'll keep building on this strong foundation to widen our impact in the months and years ahead. And now I'd like to turn the call back to the operator for Q&A. Operator, please go ahead.
Sarah James
analystThis is Gaby calling in for Sarah. Nice work on the quarter. I'd like to begin with the fact that you posted a really impressive EBITDA beat. Could you share a bit more detail about what was behind it? And from what I can tell, you've got plenty of expansion plans in the works, and the progress on closing the care gap seems to be going extremely well. So while you're growing that business, is there anything on the expense side that ought to concern us?
Norman Rosenberg
executiveAbsolutely. Gaby, this is Norm. I'll handle the first half of your question. As for the EBITDA beat, yes, I'd direct you to the gross margin line. Our blended gross margin for the quarter came in at 36%. That isn't unusual when you review the history — we've hit that level previously — but it was the strongest margin we've recorded since Q4 of 2022, a period when COVID revenue and some other items pushed that figure upward. We've consistently stated that we expect a blended gross margin somewhere around 33% to 35%. There are several moving parts. Certain factors gave us a lift this quarter, and while some of them won't repeat, others simply reflect the situation with Mobile Health margins, which I'll get into. Mobile Health margins stood at 38.8%, and they got a boost because the earliest programs — the first sites shut down under the migrant programs — happened to be the ones that generally carried lower margins. That wasn't really planned that way, but it's how things unfolded. As a result, we saw a more favorable mix inside the migrant program. Beyond that, we had a fairly solid mix across mobile health overall, so I'd say our benefit came from gross margins running somewhat above what we'd anticipate. That accounted for a large share of it. Aside from that, SG&A was kept under decent control. And as we noted, it fell 14% compared with a year earlier. We've been doing quite a bit of cost reduction and rationalization, and part of that paid off too.
Lee Bienstock
executiveGaby, this is Lee. Regarding your question, I'll address next year too. So my view is that we will keep putting money into the fast growth and swift expansion we described, especially when it comes to the payer programs. As I said, we're growing throughout the West Coast. And next year we will always be investing and staying very focused on delivering a high-quality product along with a strong patient experience. and definitely making certain that our customers — our amazing customers — plus our payer partners, our municipal partners, and our hospital systems are extremely pleased and satisfied with what we provide, and we will always lean in that direction. And we'll be putting money into that. So that showed up in the EBITDA percentage range guidance we gave for next year too. Those investments appear in it.
Pito Chickering
analystWhen we look at the 2025 guidance, in the prior quarter you gave a figure of $400 million for base business revenues with a 10% base margin, as I recall. You've now, I believe, put $50 million of migrant revenues into the guidance, and that seems to suggest the base business is growing more slowly. On margin, my understanding was that the guidance was a floor of 10%, and now it's a range of 8% to 10%. So the question, I suppose, is what changed, if anything, relative to what was said about guidance on the last quarter's call?
Lee Bienstock
executiveSure thing. This is Lee. I'll handle that. Appreciate the question. For the coming year, our aim in issuing guidance was to provide direction on where next year is headed and to incorporate our expectation for the migrant contribution. I also want to stress strongly that this work falls squarely within our population health efforts. Everything is medical in nature. We are winding down the HPD sites, which included certain ancillary services. All of that will be wound down by the end of this year. So as we move into next year, the focus will really be on services tied to infectious disease control and screening, vaccinations, urgent care, depression screenings, and other behavioral health resources we provide, and that is truly where the work will be concentrated next year. Then we also wanted to communicate that basically, as that work carries on into next year, it keeps using resources that we will ultimately shift over to base business growth; so that's what you're seeing there, as the resources move away from the migrant-related work, that will keep transitioning over to the base business and all the payer programs and all the growth opportunities we are expanding on at present. So that's essentially what next year will look like. And also the EBITDA range I referenced to Gaby in response to her question reflects a great deal of the investments we will be making in that expansion, especially on the payer programs, on our PCP program, as well as certain investments we will be making on the municipal and hospital system side. And once again, that covers rapid expansion along with excellent quality of service. So we factored that into our adjusted EBITDA percentage range.
Pito Chickering
analystAll right, so let me just confirm I've got this right. In a sense, during the prior quarter it was 10% on the $400 million — and at present we have greater revenue but a smaller margin. The reason is that the migrant is essentially at a reduced margin, pulling those resources away, and so unless we redirect that elsewhere, it acts as a drag on the coming year's EBITDA.
Lee Bienstock
executiveThat's right. And beyond that, bear in mind too that we are putting money into growing into additional markets for a number of our payer program partners. Plus, we have several opportunities, national scaling opportunities, that you will watch us expand into further markets in the next year as well.
Norman Rosenberg
executiveCorrect — this is Norm here. I'd say the picture is somewhat more layered than that. We've discussed those initiatives aimed at trimming expenses, through which we aim to properly size the company so that SG&A remains at a set proportion of revenues. Working through this in a highly detailed, bottom-up fashion, we're discovering certain expenses that perhaps ought to stay, meaning that when Lee mentions investment, that isn't simply a matter of writing bigger checks. Sometimes it involves retaining a portion of our existing expense base so growth can carry on. Take, for instance, relocating individuals involved with the migrant programs — extremely skilled, high-caliber folks — into different areas of the company, where they can assist in expanding the payer programs or a few of the other initiatives underway. Strictly speaking, that reflects an expense already on the books that remains, yet it's being shifted elsewhere. So when we examine this and carry out our detailed, bottom-up forecasts, it appears we ought to incorporate a modest degree of caution regarding our expected EBITDA margin.
Pito Chickering
analystAll right, that's helpful. Now a brief second question. When it comes to the care gap closure agreements that are being inked, and that segment is expanding quickly, what do those margins look like compared with company averages? And while you're putting money into the business, will that become a weight on margins as it continues to scale?
Lee Bienstock
executiveFor sure. We set our contract pricing to match the margins we've historically achieved; across every one of the care gap closure initiatives, we're working out tailored pricing. As a result, at the gross margin line we're protecting those margins and trying to keep doing so, though expansion will require spending on our part, similar to what prior projects showed us in earlier years — when growth moves fast, ramping up genuinely requires investment from us. We're putting people through training; we're standing up additional bases. We're ensuring that in certain situations we have more staff than strictly needed, so that we can guarantee the truly outstanding quality we intend to provide for these extremely large national payers. That means we're making certain it has every resource required to succeed in delivering a phenomenal patient experience and, beyond that, results that matter greatly to the payers; after some time passes, we fine-tune and remove a portion of those expenses. So every bit of that is factored into the guidance. and that's roughly the level of detail we were looking to provide on this call.
Ryan MacDonald
analystRyan, first off, just to clear something up about '25. In your prepared remarks, I believe you mentioned a non-migrant municipal population health business, and that the expectation for it was lower, in the $240 million to $260 million range, compared with the earlier guidance of $280 million to $300 million. Could you explain what you meant by that?
Lee Bienstock
executiveSure, Ryan, good to talk with you. The base business we described will land between $240 million and $260 million, and that's a revision from what we gave on earlier calls, again reflecting the fact that some migrant-related revenues are persisting through the end of this year, when we had expected them to taper off more around Q3. As for the additional programs, many of the ones we're launching now in municipal health care relate to population health, delivering services, again, consistent with what we've done as a company from the start, delivering services to underserved populations, uninsured populations, to our veterans, working with the Indian health system, with state and municipal population health systems to deliver things such as mobile x-ray, vaccinations, behavioral health care, infectious disease screening, annual wellness visits to our municipal partners, especially those genuinely seeking a way to bring care into underserved communities. Those same programs are what we're scaling now into next year.
Ryan MacDonald
analystUnderstood. All right. So that's simply a result of the perhaps faster wind down — you'll be gathering a larger portion of it during '24, and less than you first anticipated during '25.
Lee Bienstock
executiveAre you referring to — no, during '24, that figure was $240 million to $260 million. For the coming year, we provided our revenue guidance of $410 million to $450 million. That covers every program the company has underway.
Ryan MacDonald
analystAll right, that's useful. So next, I'd like to ask about the — you mentioned something regarding the payer side of things, with the problems around star ratings and how that, in a way, opens a door for you to grow faster across the Northeast. Could you speak to how the pipeline has grown or widened since we got that Star rating news? And clearly, closing care gaps strikes me as perhaps some easy wins that could help these payers boost their ratings down the road. But what kind of direct reaction have you received from health plans and payers you might work with, in the wake of that update?
Lee Bienstock
executiveRyan, you've got it exactly. So truly, ever since that update, which arrived like a burst across the Q3 earnings calls of many payers, what we essentially came to understand is that payers have to close these care gaps. They weigh on their financials, and they weigh on the access their patients receive. And gaps in care exist among their patients that must be addressed. If not, patients may grow sicker, and chronic conditions may become more acute. And clearly, when that occurs, it's terrible for the patients. Their health outcomes deteriorate, yet it also clearly grows more costly for the payers, since their members are essentially raising their utilization of the health plan by getting sicker. So our modality, our entire program, is about being proactive, about going into those patients' homes and closing those care gaps. Or often, we enter a patient's home and, for instance, perform a diabetic retinal exam, a bone density scan, or a colon cancer screening. And sure enough, we discover the patient is at risk for a fall and break, or at risk for vision impairment or blindness. And clearly, we're focused on ensuring the follow-up care too, collaborating with the plans to ensure that follow-up care exists. So again, the patient's condition does not precipitate. All of that aligns perfectly with what payers truly require at present, which is closing those care gaps, lowering utilization, enhancing health outcomes, which in the end will be financially better for them and will lift their profitability. Since that occurred, we've witnessed 2 things. We've witnessed our traction with various payers rise. So we're signing newer or bringing in newer payer partners that we lack today into the pipeline. And we're seeing the payers we already work with send us more patients to address. So we're seeing both. That's why we're seeing the acceleration. We're investing very heavily into that right now.
Lee Bienstock
executiveMuch appreciated. I really appreciate it. I appreciate all of you being here with us on this call, and we're eager for the one that follows. Take care.
Operator
operatorThis concludes today's conference. Thank you for attending. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.